Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$59.00T
24h Vol:
$9.86B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  HAE

Haemonetics Corp

HAE
74 / 100
High Quality
$72.48arrow_drop_down-1.39%-$1.02

Performance History

Stocklytics logo
Key Stats
Open$74.86
Prev. Close$74.90
EPS2.46
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.73B
PE Ratio29.88
LOWHIGH
Day Range73.02
74.98
52 Week Range70.74
95.26
Ratios
P/B Ratio3.96
Revenue$1.16B
Operating M. %16.04%
Earnings$115.40M
Earnings Growth %166.05%
EBITDA Margin %25.08%
ROE %14.72%
EPS2.46

Score Breakdown

74vs 53. Market Avg.

All Score 74 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

HAEMARKET
Value5039
Quality8240
Ownership019
Growth5046
Dividends-37
warning

Haemonetics Corp's Sales growth rate in the last 3 years of 15.47% is modest compared to market average of 18.54%. This indicates HAE could be a bad value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$765.00
24H (%)arrow_drop_down-0.89%
24H ($)-$6.91
MARKET CAP$726.87B
PRICE$513.41
24H (%)arrow_drop_down-2.26%
24H ($)-$11.90
MARKET CAP$474.87B
PRICE$160.98
24H (%)arrow_drop_up0.11%
24H ($)$0.19
MARKET CAP$387.76B
PRICE$129.03
24H (%)arrow_drop_up0.14%
24H ($)$0.19
MARKET CAP$326.96B

About Haemonetics Corp (HAE)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Christopher A. Simon
Headquarters
Boston
Employees
3034
Exchange
NYSE
add Haemonetics Corp to watchlist

Keep an eye on Haemonetics Corp

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Haemonetics Corp's (HAE) price per share?

The current price per share for Haemonetics Corp (HAE) is $74.28. The stock has seen a price change of $1.07 recently, indicating a 1.46% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Haemonetics Corp (HAE)?

For Haemonetics Corp (HAE), the 52-week high is $95.26, which is 28.24% from the current price. The 52-week low is $70.74, the current price is 5% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Haemonetics Corp (HAE) a growth stock?

Haemonetics Corp (HAE) has shown an average price growth of -8.43% over the past three years. It has received a score of 43 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Haemonetics Corp as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Haemonetics Corp (HAE) stock price performance year to date (YTD)?

As of the latest data, Haemonetics Corp (HAE) has a year-to-date price change of -12.8%. Over the past month, the stock has experienced a price change of -8.67%. Over the last three months, the change has been -9.39%. Over the past six months, the figure is -15.99%. Looking at a longer horizon, the five-year price change stands at -14.75%.

question_mark
Is Haemonetics Corp (HAE) a profitable company?

Haemonetics Corp (HAE) has a net income of $115.4M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 52.63% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 16.04% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.17B, with a revenue growth rate of 17.67%, providing insight into the company's sales performance and growth. The gross profit is $615.1M. Operating income is noted at $156.03M. Furthermore, the EBITDA is $274.04M.

question_mark
What is the market capitalization of Haemonetics Corp (HAE)?

Haemonetics Corp (HAE) has a market capitalization of $3.77B. The average daily trading volume is 497.21K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.